Luminal type breast cancer is known to show limited response to chemotherapy; hence, it is difficult to accomplish pCR, whereas HER2-positive or TN breast cancer has high sensitivity to chemotherapy as a subset of these subtypes can be pathologically eliminated (pCR) by NAC [2]. The gene discussed is ERBB2; the disease is breast carcinoma.